
Overview
Bioresearch Pharma is a company that repurposes existing topical drugs for dermatological applications, focusing on conditions such as androgenetic alopecia and psoriasis. They offer BRP-011, a therapy aimed at promoting hair growth, and BRP-007, a new treatment for plaque psoriasis with a unique mechanism of action. The company develops advanced medicines by utilizing well-tested therapeutic substances for new indications and creating novel drug formulations.
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $0 | |
| Profit allocation | Loss covered | |
| Capital expenditure | $991 | |
| Planned capital expenditure (next year) | $12,557 | |
| Management board pay | $50,176 | |
| Audit firm | ECOVIS Poland Sp. z o.o. |
Filing timeliness
Financial statements were filed on time, on average 18 days early. All were audited by a statutory auditor.
- 202524/06/2026
- 202401/07/2025
- 202327/06/2024
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Dermatology medicines
- Anti-inflammatory medicines
- Medicines for androgenetic alopecia
Website technology
- Website
- WordPress
Authorized Representatives
Manner of representation
In the case of a one-person management board, the sole member of the management board is entitled to independently represent the company. In the case of a multi-member management board, representation of the company requires the joint action of two members of the management board or one member of the management board jointly with a commercial proxy.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2022-03-09.
09 1090 1098 0000 0001 5972 4948
54 1020 1169 0000 8502 0878 7840
80 1020 1169 0000 8502 0805 1239
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Mar 22, 2024 | Transformation |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Nov 25, 2025 | Aid for SMEs for innovation support | $1.5M$1,506,775 | Prezes Banku Gospodarstwa Krajowego |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Goodwill Pharma Polska sp. z o.o. | $664,724.30 | goodwillpharma.com | ||
| Polmex Pharma Biniecki sp. k. | $302,741.93 | polmex-pharma.pl | ||
| PNN Pharmaceuticals sp. z o.o. + limited partnership | $267,897.16 | pnn.com.pl | ||
| Kosma Pharma Group sp. z o.o. | $198,964.09 | lpc37.pl | ||
| PRO Aktiv sp. z o.o. | $164,060.83 | proaktiv.pl | ||
| Magnapharma sp. z o.o. | $171,549.33 | magnapharma.pl | ||
| Histapharma sp. z o.o. | $68,296.48 | histapharma.pl | ||
| RED Pharma Laboratories Central Europe East sp. z o.o. | $44,616.98 | red-pharma.com | ||
| Emergopharm Holding sp. z o.o. | $37,906.34 | emergopharm.com | ||
| Ethifarm sp. z o.o. | $14,540.63 | ethifarm.pl |
Change history
| Date | Event | |
|---|---|---|
| 2024-10-18 | Share capital increase (168,190.00 PLN → 228,989.80 PLN) | |
| 2024-05-07 | Share capital increase (162,500.00 PLN → 168,190.00 PLN) | |
| 2024-03-14 | Entered in the register |
FAQ
Last updated: 2026-10-03